Omrix Biopharmaceuticals Inc. (OMRI) is in the Pharma Industry

• Sort by
• View by Content Type
• View Related Content by Tag

• J&J to Buy Breast Implant Firm Mentor For $1.1 Billion

  By Susan Kelly and Lewis KrauskopfCHICAGO/NEW YORK (Reuters) - Johnson & Johnson JNJ will buy breast implant maker Mentor Corp MNT for $1.07 billion as the diversified healthcare giant pushes into the market for cosmetic medical procedures.J&J's tender offer for Mentor, announced on Monday, is $31 per share, a 92...

  News items 2008-12-01

  Tags: Johnson & Johnson, Breast, Mergers & Acquisitions, Corporate Law, Healthcare, Allergan Inc., Mentor Corp., Omrix Biopharmaceuticals Inc.

• King Pharma to Acquire Alpharma For About $1.6 Billion

  By Toni ClarkeBOSTON (Reuters) - King Pharmaceuticals Inc KG said on Monday it has agreed to acquire Alpharma Inc ALO for about $1.6 billion, ending a fractious takeover tussle and expanding King's presence in the market for pain drugs.King's offer of $37 a share has been accepted by Alpharma's board...

  News items 2008-11-24

  Tags: Revenue, Pharmaceutical Company, King Alpharma, Banc Of America Securities LLC, Alpharma Inc., Johnson & Johnson, King Pharmaceuticals Inc., Omrix Biopharmaceuticals Inc., Pain Therapeutics Inc.

• JNJ / Omrix: Potential Synergies

  Eben Tessari submits: Johnson & Johnson JNJ and Omrix Biopharmaceuticals OMRI, a biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced a definitive agreement whereby Omrix will be acquired for approximately $438 million in a cash tender offer. Omrix is expected to operate as a stand-alone entity reporting...

  External links 2008-11-24

  Tags: Healthcare, Eben Tessari, Johnson & Johnson, Omrix Biopharmaceuticals Inc.

• Omrix Biopharmaceuticals, Inc. Q3 2008 Earnings Call Transcript

  Question-and-Answer SessionOperator Operator instructions And our first question will come from the line of Amit Hazan with Oppenheimer. Please proceed. Amit Hazan – Oppenheimer Thanks. Hi. Good morning, guys. Nice quarter. And welcome, Asaf. Asaf Alperovitz Thank you, Amit. Robert Taub Good morning, Amit. Amit Hazan...

  Earnings calls 2008-11-24

  Tags: Margin, Call Transcript, Earnings, Omrix Biopharmaceuticals Inc., Oppenheimer, Sales Strategy, Research & Development, Sales Force Management, Financial Accounting, Sales, Business Operations, Finance, Seeking Alpha

• Omrix Biopharmaceuticals, Inc. Q2 2008 Earnings Call Transcript

  Question-and-Answer SessionOperator Operator instructions Your first question comes from the line of Amit Hazan from Oppenheimer. Please proceed. Amit Hazan – Oppenheimer Thanks Good afternoon guys. Can you hear me okay? Robert Taub Yes, good afternoon, Amit. Sophie Hobbs Hi Amit. ...

  Earnings calls 2008-09-02

  Tags: Omrix Biopharmaceuticals Inc.

• Omrix Stops the Bleeding; Has SanDisk Started Healing?

  Shlomi Cohen submits: The soaring dollar and tumbling oil prices set us up, quite unexpectedly, in the middle of the summer vacation, with one the best weeks we've had recently, with the Russell 2000 Index rising by 2.5% over the week and the Nasdaq 100 climbing 5.5%. The experts...

  External links 2008-08-13

  Tags: SanDisk Corp., Gadgets, Biotech, Omrix Biopharmaceuticals Inc.

• Omrix Biopharmaceuticals Inc. Earnings Call Transcript

  Question-and-Answer Session Operator Operator Instructions. And our first question will come from the line of Amit Hazan with Oppenheimer, please proceed. Amit Hazan - Oppenheimer Thanks. Hi, Good Morning guys. Robert Taub Good Morning Amit Sophie Hobbs Good morning Amit. Amit Hazan - Oppenheimer First question...

  Earnings calls 2008-05-09

  Tags: Omrix Biopharmaceuticals Inc.

• OMRIX Biopharmaceuticals to Webcast Analyst & Investor Day on Thursday, March 27, 2008

  NEW YORK -- OMRIX Biopharmaceuticals, Inc. ("OMRIX" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today announced that it will webcast its Analyst and Investor Day, which will be held on Thursday, March 27, 2008 at the NASDAQ MarketSite in New...

  Research articles 2008-03-20

  Tags: Company, Nasdaq Stock Market Inc., Omrix Biopharmaceuticals Inc., SEC, Webcast

• OMRIX Biopharmaceuticals Provides Update on its Fibrin Patch Product Candidate

  NEW YORK -- OMRIX Biopharmaceuticals, Inc. ("OMRIX" or the "Company")(NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that it has received a letter from the Food and Drug Administration providing the Company approval to commence a Phase II clinical trial in the...

  Research articles 2008-03-17

  Tags: Company, FDA, Government, Omrix Biopharmaceuticals Inc., SEC

• OMRIX Biopharmaceuticals to Webcast Presentation at the Citi Small & Mid-Cap Conference

  NEW YORK -- OMRIX Biopharmaceuticals, Inc. ("OMRIX" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that Robert Taub, Chief Executive Officer, is scheduled to give a company presentation at the Citigroup Small & Mid-Cap Conference on Wednesday, March 19,...

  Research articles 2008-03-13

  Tags: Citigroup Inc., Company, INTERNET, Omrix Biopharmaceuticals Inc., Webcast

• OMRIX Biopharmaceuticals to Webcast Presentation at the Cowen and Company 28th Annual Health Care Conference

  NEW YORK -- OMRIX Biopharmaceuticals, Inc. ("OMRIX" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that Robert Taub, Chief Executive Officer, is scheduled to give a company presentation at the Cowen and Company 28th Annual Health Care Conference on...

  Research articles 2008-03-11

  Tags: Benefits, Company, conference, HEALTHCARE, INTERNET, Omrix Biopharmaceuticals Inc., SEC, SOFTWARE, Webcast

• OMRIX Biopharmaceuticals, Inc. Q4 2007 Earnings Call Transcript

  Question-and-Answer SessionOperator Operator Instructions. Your first question comes from the line of Matthew Dodds with Citigroup. Please proceed. Greg Good morning. This is actually Greg call in for Matt, he is out today inaudible on the call. Robert Taub Good morning Greg. Greg Hi, how are...

  Earnings calls 2008-03-06

  Tags: Omrix Biopharmaceuticals Inc.

• OMRIX Biopharmaceuticals Q3 2007 Earnings Call Transcript

  Question-and-Answer SessionOperator Operator Instructions Eli Kammerman from Cowen & Company. Please proceed. Eli Kammerman - Cowen & Company Thanks very much and good morning. Robert Taub Good morning. Ana Stancic Good morning, Eli. Eli Kammerman - Cowen & Company First question is, what was the stock options amounted in...

  Earnings calls 2007-11-05

  Tags: Omrix Biopharmaceuticals Inc.

• OMRIX Biopharmaceuticals Files Registration Statement for Proposed Public Offering of Common Stock

  NEW YORK -- OMRIX Biopharmaceuticals, Inc. ("OMRIX" or the "Company") (NASDAQ: OMRI), a commercial-stage biopharmaceutical company that develops and markets biosurgical and antibody-based products, announced today that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission relating to a proposed public offering of an...

  Research articles 2006-12-04

  Tags: Omrix Biopharmaceuticals Inc., SEC

Additional Resources

• Johnson & Johnson Announces Definitive Agreement to Acquire Omrix

  Omrix's Biopharmaceutical Expertise Complements ETHICON's Industry-Leading Surgery Portfolio NEW BRUNSWICK, N.J. and NEW YORK, Nov. 24 /PRNewswire-FirstCall/ -- Johnson & Johnson and Omrix Biopharmaceuticals, Inc. , a fully integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today announced a definitive agreement whereby Omrix...

  Articles 2008-11-24

• Omrix Biopharmaceuticals to Webcast Presentation at Credit Suisse Annual Healthcare Conference

  NEW YORK -- Omrix Biopharmaceuticals, Inc. ("Omrix") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that Nissim Mashiach, President & Chief Operating Officer, is scheduled to give a company presentation at the Credit Suisse Annual Global Healthcare Conference on Friday, November 14,...

  Articles 2008-11-06

• Omrix Biopharmaceuticals Announces Third Quarter 2008 Financial Results

  NEW YORK -- Omrix Biopharmaceuticals, Inc. ("Omrix" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today announced financial results for the third quarter ended September 30, 2008: * Third quarter 2008 total revenues were $21.3 million, a 34% increase,...

  Articles 2008-11-06

• Omrix Biopharmaceuticals to Webcast Presentation at Rodman & Renshaw Annual Healthcare Conference

  NEW YORK -- Omrix Biopharmaceuticals, Inc. ("Omrix") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that Nissim Mashiach, President & Chief Operating Officer, is scheduled to give a company presentation at the Rodman & Renshaw Annual Healthcare Conference on Monday, November 10,...

  Articles 2008-11-04

• Omrix Biopharmaceuticals Reschedules its Third Quarter 2008 Financial Results and Conference Call to an Earlier Time on November 6, 2008

  NEW YORK -- OMRIX Biopharmaceuticals, Inc. ("OMRIX" or the "Company") (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that it has rescheduled the announcement of its financial results and accompanying conference call for the third quarter ended September 30, 2008 to an...

  Articles 2008-11-03

• Zacks Releases New Stock Picks from +21.7% Momentum Strategy: Omrix Biopharmaceuticals, Spartan Motors, Indiana Community Bancorp, Interactive Brokers Group and DXP Enterprises

  CHICAGO -- The latest stock picks from the Value Method (VM1) strategy are being spotlighted today by Zacks, the nation's largest independent stock research firm. This strategy surged +21.7% during the first half 2008, while the S&P 500 dropped by nearly -12%. In fact, from 2001 through 2007, the strategy...

  Articles 2008-10-30